Navigation Links
Onyx Pharmaceuticals Appoints Bill Ringo to Board of Directors
Date:2/3/2011

EMERYVILLE, Calif., Feb. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that it has named Bill Ringo to its Board of Directors. Mr. Ringo currently serves as Executive Partner at Sofinnova Ventures, a venture capital firm based in Silicon Valley and as a Senior Advisor to Barclays Capital.

"Bill's impressive industry knowledge, commercial oncology experience and broad sector expertise will be invaluable as we look to expand our commercial presence with a potential second marketed product, carfilzomib, and continue to broaden our development pipeline," said N. Anthony Coles, M.D., president, chief executive officer and member of the board at Onyx.  

Mr. Ringo has 38 years of experience in the pharmaceutical, biotechnology and med-tech industries. Prior to his most recent assignments, he served as senior vice president of strategy and business development for Pfizer, retiring in 2010. He also spent 28 years at Eli Lilly & Company, serving as product group president for oncology and critical care, president of the infectious diseases business unit, vice president of sales and marketing for U.S. Pharmaceuticals, and as a member of the corporate operating committee. Mr. Ringo was the former president and chief executive officer of Abgenix, a biotechnology firm focused on developing human antibodies to treat cancer that was acquired by Amgen in April 2006. He is the current chairman of Sangamo BioSciences and serves as a director on the Alvine Pharmaceuticals, Inc. and BioCrossroads boards. Mr. Ringo holds a bachelor's degree and masters in business administration from the University of Dayton.

"It is an honor to join the Board of Directors at a time when Onyx is making the transition into a leading biotechnology company with a strong commercial presence and long-term growth opportunities through its pipeline," said Ringo. "I believe Onyx will continue to raise the bar in providing innovative and effective treatment options for cancer patients in need."

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx Pharmaceuticals, Inc., or Onyx, within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the expected contributions of Mr. Ringo the commercial potential of carfilzomib and Onyx's growth opportunities.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc ... Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: ... , Results of the comparative usability study demonstrate that a dictation-based method (“NLP ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
Breaking Medicine News(10 mins):